 previous article in this issue | next article in this issue  |
|
Document Details : Title: A case series of embryonal rhabdomyosarcoma of the head and neck in adults Author(s): WAGEMANS J, BEUSELINCK B, NUYTS S, SCIOT R, DELAERE P, VANDER POORTEN V, DUMEZ H, HERMANS R, SCHÖFFSKI P, VAN DEN BOGAERT W, JORISSEN M, CLEMENT PMJ Journal: Acta Clinica Belgica Volume: 65 Issue: 6 Date: 2010 Pages: 404-410 DOI: 10.2143/ACB.65.6.1002447 Abstract : Embryonal rhabdomyosarcoma (RMS) is a rare malignant mesenchymal tumour that is believed to arise from cells committed to a skeletal muscle lineage. The head and neck region is among the most frequent locations for embryonal RMS in adults. We present a retrospective review of seven patients treated in our institution between 2000 and 2008. The age at diagnosis ranged from 19 to 41 years. One patient received primary surgery followed by adjuvant radiotherapy. Six inoperable patients were treated along a single chemotherapy protocol: the VIA-VIP regimen (a combination of vincristine, ifosfamide and doxorubicin (VIA) in alternation with etoposide, ifosfamide and cisplatin (VIP) administered in 3-weekly cycles), followed by local therapy, involving radiation therapy and/or surgery. An objective response to chemotherapy was observed in all six patients. Three out of seven patients remain disease-free with a median follow up of 4.5 years. Although the prognosis of head and neck embryonal RMS is worse in adults than in children, a multimodality treatment combining surgery, radiotherapy and intensive chemotherapy is feasible and effective in this population. |
